ibalizumab
Sign in to saveIbalizumab, sold under the brand name Trogarzo, is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.
In the Vinony graph
Vinony's link graph records 296 inbound references to ibalizumab, and connects out to tenofovir alafenamide, monoclonal antibody and humanized antibody.
Vinony files it under Antiviral drugs, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Vinony links it to 12 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 458273983
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- CD4
- Drug.tradename
- Trogarzo
- Drug.MedlinePlus
- a618020
- Drug.DailyMedID
- Ibalizumab
- Drug.routes_of_administration
- Intravenous (IV)
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AX23
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 680188-33-4
- Drug.DrugBank
- DB12698
- Drug.ChemSpiderID
- none
- Drug.UNII
- LT369U66CE
via Wikipedia infobox
Research
112 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 1 more fact
- subject has role
- monoclonal antibody
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Development
- References
- External links
Ibalizumab, sold under the brand name Trogarzo, is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.
On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved ibalizumab for multidrug-resistant HIV-1. It is used in combination with other antiretroviral drugs. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “ibalizumab” article, available under the CC BY-SA 4.0 licence.